Myocardial injury induced by oxitinib in a patient with advanced lung adenocarcinoma

Published on Feb. 15, 2023Total Views: 807 times Total Downloads: 393 times Download Mobile

Author: Guo-Yin LI ¹ 2 Shu-Yuan LIN ² Li BIAN ²  Ying SUN ¹

Affiliation: 1. Department of Pharmacy, Lianyungang First People’s Hospital (the First Affiliated Hospital of Kangda College of Nanjing Medical University) , Lianyungang 222000, Jiangsu Province, China 2. Pharmacy of Lianyungang Xuwei New District People’s Hospital, Lianyungang 222000, Jiangsu Province, China

Keywords: Oshtinib Myocardial injury Adverse drug reactions case report

DOI: 10.19960/j.issn.1005-0698.202302015

Reference: Guo-Yin LI, Shu-Yuan LIN, Li BIAN, Ying SUN.Myocardial injury induced by oxitinib in a patient with advanced lung adenocarcinoma[J].Yaowu Liuxingbingxue Zazhi,2023, 32(2): 233-237.DOI: 10.19960/j.issn.1005-0698.202302015.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

A 70-year-old male patient with stage IV left lower lung adenocarcinoma was treated with gefitinib. After taking it for 3 months, the patient developed drug resistance and was treated with oxitinib instead. After 5 months of continuous administration of oxitinib, the patient suffered from sudden dyspnea, orthostatic breathing with sweating, and edema of both lower limbs. The ECG showed ST-T changes, hsTnI 11 025.5 pg · mL^-1, CK 798 U · L^-1, CK-MB 3.1 ng · mL^-1, NT-proBNP 3 191 pg · mL^-1, and LVEF decreased from 58% to 30%, with a decrease of more than 10% from the baseline and lower than the lower limit of the normal value. It was considered as acute myocardial infarction and heart failure. The adverse reaction correlation score was 6 points by using the Roche Adverse Drug Re-action Assessment Scale. It was evaluated by Naranjo’s score scale that the adverse reaction of myocardial injury was “likely” caused by oxitinib. Myocardial injury improved after drug withdrawal and symptomatic support treatment.

Full-text

Please download the PDF version to read the full text: download

References

1. 中国心血管病风险评估和管理指南编写联合委员会. 中国心血管病风险评估和管理指南[J]. 中国循环杂志, 2019, 34(1): 4-28. DOI: CNKI:SUN:ZGXH.0.2019-01- 003.

2. 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会 CSCO肿瘤治疗相关心血管毒性防治指南 2021[M]. 北京: 人民卫生出版社, 2021: 15-23.

3. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reac-tions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.

4. 安涛, 韩森. 肺癌靶向治疗药物的心血管毒性[J]. 中国肿瘤临床, 2021, 48(6): 311-316. [An T, Han S. Cardio-vascular toxicity of targeted drugs for lung cancer[J] Chinese Clinical Oncology, 2021, 48(6): 311-316.] DOI: 10.3969/j.issn.1000-8179.2021.06.557.

5. Anand K, Ensor J, Trachtenberg B, et al. Osimertinib induced cardio-toxicity: A retrospective review of FDA adverse events reporting system (FAERS)[J]. J Clin Oncol, 2019, 37: 172-178. DOI: 10.1200/jco.2019.37.15_suppl.9044.

6. 唐倩雯, 徐倩. 甲磺酸奥希替尼片治疗晚期肺腺癌致急性充血性心力衰竭1例[J]. 药物流行病学杂志, 2021, 30(11): 782-784.[Tang QW, Xu Q. A case of acute congestive heart failure caused by advanced lung adenocar-cinoma treated with oxitinib mesylate tablets[J]. Journal of Pharmacoepidemiology, 2021, 30 (11): 782-784.] DOI: 10.19960/j.cnki.issn1005-0698.2021.11.015.

7. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125. DOI: 10.1056/NEJMoa1713137.

8. Parkes S. Chronic health conditions in adult survivors of childhood cancer[J]. N Engl J Med, 2006, 355(15): 1572-1582. DOI: 10.1056/NEJMsa060185.

9. Herrmann J, Yang EH, Iliescu C, et al. Response by herrmann et al to letter regarding article, "vascular toxicities of cancer therapies: the old and the new-an evolving avenue"[J]. Circulation, 2016, 133(13): 1272-1289. DOI: 10.1161/CIRCULATIONAHA.116.024415.